Pfizer and biontech receive positive chmp opinion for lp.8.1-adapted covid-19 vaccine in the european union

New york and mainz, germany, july 25, 2025 — pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) announced today that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has recommended marketing authorization for the companies' lp.8.1-adapted monovalent covid-19 vaccine (comirnaty® lp.8.1) for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. the adaptation is based on the recommendation from the ema's emergency task force (etf) to update covid-19 vaccines to target the lp.8.1 variant for the 2025-2026 season. the etf stated that “targeting lp.8.1 will help maintain the effectiveness of the vaccines as sars-cov-2 continues to evolve.”2
BNTX Ratings Summary
BNTX Quant Ranking